Breaking News – Another Treatment Option Approved for MPNs CTI BioPharma Announces FDA Accelerated Approval of VONJO™ (pacritinib) for the Treatment of Adult Patients with Myelofibrosis and Thrombocytopenia Pacritinib a novel JAK2/FLT3 and IRAK inhibitor has been approved for MF patients with low platelets and we hope it will be widely available soon with hopefully…
Have you had COVID 19 infection? We need to find out more about how long covid affects people like you – can you help us? We would like to share with you an opportunity to take part in a study to investigate the impact of COVID-19 infection in people with myeloid blood cancers. What is…
The MOMENTUM study is a global, randomized, double-blind clinical trial evaluating momelotinib (MMB) in myelofibrosis patients who are symptomatic and anaemic and previously treated with an approved JAK inhibitor. The trial met all of its primary and secondary endpoints, achieving statistically significant benefit on symptoms, anaemia and splenic size. Professor Claire Harrison, Guy’s & St…
We have some important and very welcome news to share with you about a new drug for myelofibrosis patients. After a long and complicated appraisal process, the National Institute for Clinical Excellence (NICE) has decided that fedratinib is to be made available to the NHS. The drug, to be distributed under the name Inrebic, is…
As you will be aware the government has launched a 3rd dose of COVID vaccination for selected patients who may not have mounted an adequate response to the first two doses. Separately adults over 50 years and those in original vaccine groups 1-9 are to be offered a so-called booster dose. The type of vaccine…
MPN Voice is committed to providing health care information and support through a variety of channels. Please can you take some time to help us to understand your communication preferences for receiving information about MPNs. All answers will be anonymous and we will use the results to develop the support needed to MPN patients and…
We need your help – will you share your story on our website? We are currently updating and reviewing the information on our website. The real stories shared by the MPN Community are an important section where new patients and their families can be informed and encouraged by stories of how different people are living…
We would like to thank everyone who completed the MPN COVID-19 vaccination survey in March. The survey was conducted by the teams at Guy’s & St Thomas’ Hospital to assess the various aspects regarding COVID vaccines in people with MPNs, including their opinions and experiences regarding vaccination which is of major interest to aid future…
Researchers at Guy’s and St Thomas’ NHS Foundation Trust are carrying out research to investigate how patients with MPN and also CML respond to vaccination against Covid-19. They would like to recruit patients with a known MPN – who have either not yet received a second dose OR are less than 6 weeks from second…
The MPN Voice medical advisory committee wants to share with our community the following: Thrombosis associated with low platelets is an exceedingly rare event in patients receiving the Oxford-AZ COVID vaccine and causal relationship remains unclear. There are no confirmed reports of any specific platelet or thrombosis problems in MPN patients relating to the COVID…